V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10005357 | 10006850 | null | 65.8 | Neo-adjuvant (N) | 2017-05-23 | 2017-06-22 | CLARITY Trial | N | N | 10433241 | IBRUTINIB |
| 10005358 | 10006850 | 1.73 | null | Palliative (P) | 2019-08-09 | 2019-08-22 | Bendamustine +/- Prednisolone | N | N | 10433241 | LENALIDOMIDE |
| 10005359 | 10003343 | null | null | Radical (R) | 2019-07-18 | 2019-08-07 | METHOTREXATE | N | N | 10435233 | TRASTUZUMAB |
| 10005360 | 10003344 | 1.62 | 63 | Palliative (P) | 2018-02-18 | 2018-02-23 | AML18 PILOT TRIAL | 02 | null | 10435336 | TRASTUZUMAB |
| 10005361 | 10003345 | 1.6 | 0 | Adjuvant (A) | null | 2017-11-28 | IPILIMUMAB + NIVOLUMAB | 02 | N | 10436065 | SUNITINIB |
| 10005362 | 10003346 | null | 119 | null | 2018-03-20 | 2018-04-18 | VEDex | 02 | N | 10436355 | ALEMTUZUMAB |
| 10005363 | 10006851 | 1.61 | 49 | Palliative (P) | 2019-07-19 | 2019-08-05 | CYCLOPHOSPHAMIDE | 2 | N | 10436778 | DOCETAXEL + TRASTUZUMAB |
| 10005364 | 10006851 | 1.65 | null | Disease modification (D) | 2018-05-20 | 2018-06-11 | FEC 100 + DOCETAXEL + TRASTUZUMAB | 2 | N | 10436778 | CARBOPLATIN + EPIRUBICIN + PACLITAXEL |
| 10005365 | 10008879 | 1.47 | 55.3 | Adjuvant (A) | 2016-08-13 | 2016-08-14 | ECF | N | Y | 10438117 | MITOMYCIN INTRAVESICULAR |
| 10005366 | 10003347 | 1.69 | 73.3 | null | 2017-12-03 | 2017-12-09 | CETUXIMAB + RT | N | N | 10438823 | DHAP |
| 10005367 | 10006852 | 1.4 | null | null | null | 2017-01-26 | MEDROXYPROGESTERONE | 2 | null | 10439991 | DABRAFENIB |
| 10005368 | 10003348 | null | null | Not known (9) | 2018-07-05 | 2018-07-05 | Capecitabine (21days) + Carboplatin | 02 | N | 10440812 | FEC + DOCETAXEL + TRASTUZUMAB |
| 10005369 | 10003349 | 1.7 | 64.5 | Curative (C) | 2018-05-14 | 2018-05-25 | TEMOZOLOMIDE | N | N | 10440868 | COMPLEMENT TRIAL |
| 10005370 | 10003349 | null | 64.7 | Disease modification (D) | 2013-06-14 | 2013-07-01 | Sorafenib | N | N | 10440868 | CYTARABINE |
| 10005371 | 10003349 | 1.73 | 0 | Adjuvant (A) | 2016-05-24 | 2016-06-11 | IPILIMUMAB + NIVOLUMAB | 02 | N | 10440868 | CHLVPP |
| 10005372 | 10003350 | null | 84.7 | Palliative (P) | 2017-03-27 | 2017-03-29 | AML18 PILOT TRIAL | 99 | N | 10441548 | CAPECITABINE + MITOMYCIN + RT |
| 10005373 | 10003351 | 1.7 | 67.2 | Adjuvant (A) | 2017-12-03 | 2017-12-06 | FEC + DOCETAXEL + TRASTUZUMAB | N | N | 10441739 | MITOMYCIN |
| 10005374 | 10003352 | 1.7 | 80 | Palliative (P) | 2016-04-04 | 2016-04-04 | ECF | N | N | 10443855 | CETUXIMAB |
| 10005375 | 10003352 | null | null | Palliative (P) | 2014-10-05 | 2014-10-06 | Gefitinib: 1 to 2 & 4 onwards | N | null | 10443855 | VINORELBINE |
| 10005376 | 10003352 | null | 54.9 | Curative (C) | 2018-10-20 | 2018-12-03 | Bortezomib + CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | N | null | 10443855 | CAPECITABINE + CISPLATIN + RT |
| 10005377 | 10008880 | 1.63 | 67 | Palliative (P) | 2015-08-05 | 2015-08-05 | DABRAFENIB | N | N | 10446245 | MELPHALAN |
| 10005378 | 10008880 | null | 78 | Palliative (P) | 2018-10-11 | 2018-11-03 | CETUXIMAB | 02 | null | 10446245 | CARBO + FLUOROURACIL |
| 10005379 | 10008880 | 1.68 | null | null | 2016-08-23 | 2016-08-25 | R CODOX M | N | N | 10446245 | CYTARABINE |
| 10005380 | 10008880 | 1.65 | null | Palliative (P) | 2017-01-01 | 2017-01-05 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 10446245 | TUXEDO TRIAL |
| 10005381 | 10003353 | 1.61 | 58.3 | null | 2019-12-20 | 2019-12-21 | Cisplatin + Docetaxel +Fluorouracil | N | N | 10448950 | FEC + DOCETAXEL + TRASTUZUMAB |
| 10005382 | 10003354 | 1.72 | 57.4 | Disease modification (D) | 2018-08-03 | 2018-08-03 | CISPLATIN + FLUOROURACIL | 2 | N | 10449357 | RUXOLITINIB |
| 10005383 | 10003354 | null | 83.4 | Palliative (P) | 2014-10-20 | 2014-10-22 | Bortezomib + MELPHALAN | N | N | 10449357 | STAMPEDE TRIAL |
| 10005384 | 10003354 | 1.83 | 93.3 | Palliative (P) | 2018-09-02 | 2018-09-11 | AFATINIB | 02 | N | 10449357 | CYTARABINE |
| 10005385 | 10003354 | 1.82 | 64.9 | Palliative (P) | null | 2016-01-17 | BORTEZOMIB + THALIDOMIDE | 02 | N | 10449357 | RCEOP |
| 10005386 | 10003355 | 1.72 | 80 | Palliative (P) | 2018-06-10 | 2018-06-24 | FLAG + Idarubicin | N | Y | 10451896 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005387 | 10003356 | null | 54.4 | Palliative (P) | 2019-04-03 | 2019-04-18 | PCV | N | null | 10454036 | RCEOP |
| 10005388 | 10003357 | 1.52 | 61.6 | Curative (C) | 2019-01-14 | 2019-01-14 | Erlotinib | N | null | 10454441 | CARBOPLATIN + PACLITAXEL + RT |
| 10005389 | 10003358 | null | null | Adjuvant (A) | 2016-01-23 | 2016-02-10 | Sorafenib | 02 | null | 10454806 | HCX |
| 10005390 | 10003359 | 1.78 | 73.6 | Neo-adjuvant (N) | 2018-09-18 | 2018-10-03 | ECarboX | N | N | 10454967 | LOPP |
| 10005391 | 10003360 | 1.75 | 98.7 | Adjuvant (A) | 2013-09-25 | 2013-09-26 | IBRUTINIB | N | N | 10455731 | OXALIPLATIN |
| 10005392 | 10006856 | null | 70.6 | Neo-adjuvant (N) | 2016-09-29 | 2016-10-13 | IDELALISIB + RITUXIMAB | Y | N | 10455972 | VINORELBINE |
| 10005393 | 10003361 | 1.67 | 93.25 | Adjuvant (A) | null | 2017-10-20 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | N | N | 10456773 | CAPECITABINE + CARBOPLATIN |
| 10005394 | 10003362 | 1.7 | 0 | Palliative (P) | 2016-07-17 | 2016-07-17 | Lomustine | 02 | N | 10457159 | CHLORAMBUCIL + RITUXIMAB |
| 10005395 | 10003362 | 1.8 | 85 | Curative (C) | 2017-05-20 | 2017-05-20 | Mitomycin Intravesical | N | N | 10457159 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 10005396 | 10003363 | 1.6 | 55.7 | Curative (C) | 2018-06-20 | 2019-03-29 | Erlotinib | 02 | N | 10457248 | CHLORAMBUCIL + RITUXIMAB |
| 10005397 | 10003363 | 0 | 60.6 | Palliative (P) | 2017-02-16 | 2017-02-17 | CISPLATIN + VINORELBINE + RT | N | N | 10457248 | CHLVPP |
| 10005398 | 10003363 | 1.65 | 90.5 | Curative (C) | 2018-09-07 | 2018-09-07 | Sunitinib | N | N | 10457248 | GEFITINIB |
| 10005399 | 10003363 | null | 75.15 | Disease modification (D) | 2014-02-10 | 2014-02-14 | Nilotinib | 02 | N | 10457248 | QUASAR 2 TRIAL |
| 10005400 | 10003364 | 1.77 | null | Disease modification (D) | null | 2014-11-05 | DABRAFENIB + TRAMETINIB | N | N | 10458635 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10005401 | 10003365 | 1.7 | 85.4 | null | 2016-03-21 | 2016-04-21 | Alemtuzumab | 02 | N | 10459206 | PILOT TRIAL |
| 10005402 | 10003366 | 1.67 | 86.4 | Palliative (P) | 2016-08-04 | 2016-08-05 | FCR Oral - Cycle 1 | N | N | 10459816 | VEMURAFENIB |
| 10005403 | 10003367 | null | null | Palliative (P) | 2017-08-11 | 2017-08-12 | Dacarbazine | N | N | 10460803 | CAPECITABINE + CARBOPLATIN |
| 10005404 | 10003368 | 0 | 57 | Palliative (P) | 2017-10-31 | 2017-11-05 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | N | 10460932 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005405 | 10003369 | 1.65 | 64.9 | Disease modification (D) | 2018-09-27 | 2018-10-10 | TRASTUZUMAB | 02 | N | 10461033 | MITOMYCIN INTRAVESICULAR |
| 10005406 | 10003369 | 1.77 | 116 | Palliative (P) | 2018-10-13 | 2018-11-13 | GEFITINIB | N | Y | 10461033 | LIPOSOMAL DOXORUBICIN |